Latest Media Releases

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Immutep - S&P DJI Announces September 2024 Quarterly Rebalance (ASX:IMM)

S&P Dow Jones Indices announced today the changes in the S&P/ASX Indices, effective prior to the opening of trading on Monday, September 23, 2024, as a result of the September quarterly revi...read more

Immutep - Appendix 4E & 2024 Full Year Statutory Accounts (ASX:IMM)

To view the appendix, download the attached PDF.

INOVIQ - Appendix 4E and Preliminary Financial Report (ASX:IIQ)

To view the appendix, download the attached PDF.

Immutep Corporate Presentation (ASX:IMM)

To view the presentation, download the attached PDF.

Immutep - TACTI-003 data selected for oral presentation at ESMO 2024 (ASX:IMM)

Oral presentation will detail results from the randomized TACTI-003 Phase IIb trial in first line head & neck squamous cell carcinoma patients with any PD-L1 expression (CPS >...read more

INOVIQ - NEURO-NET validated in Parkinson's (ASX:IIQ)

INOVIQ Limited (ASX:IIQ or INOVIQ) is pleased to announce that it has further validated its NEURONET ™ technology for isolation of brain-derived exosomes in Parkinson’s Disease (PD)...read more

Immutep - First Participant Dosed in Phase I Study of IMP761 (ASX:IMM)

MP761 is designed to enhance the “brake” function of LAG-3 on T cells to restore balance to the immune system and address the underlying cause of many autoimmune diseases...read more

Immutep Quarterly Activities Report and Appendix 4C (ASX:IMM)

Entered into third and most important clinical trial collaboration and supply agreement to date with MSD to evaluate eftilagimod alfa (efti) in combination with KEYTRUDA® (pembrolizumab) an...read more

INOVIQ - Quarterly Activities Report and Appendix 4C - June 2024 (ASX:IIQ)

Lodging this quarterly update, Chairman David Williams said: “Our recent capital raise of $9.4m plus attaching options is evidence of the value shareholders place on the prospects of our ...read more

Immutep - Successful Meeting with FDA on Phase III Design in NSCLC (ASX:IMM)

-- Final discussion with the FDA, successfully concluding the regulatory preparations for the TACTI-004 Phase III trial design to evaluate efti in combination with KEYTRUDA® (pembrolizumab), MSD...read more

Immutep - Regulatory Clearance received for Phase 1 trial of IMP761 (ASX:IMM)

Study expected to enrol first participants during Q3 CY2024 SYDNEY, AUSTRALIA – 17 July 2024 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or &ldq...read more

Immutep - Positive results in TACTI-003 for 1L HNSCC cohort B patients (ASX:IMM)

Efti in combination with KEYTRUDA® (pembrolizumab) achieved a 35.5% response rate in evaluable patients (N=31), according to RECIST 1.1, among the highest recorded for a treatmen...read more

Immutep - Webcast to discuss data presented at ESMO Plenary Session (ASX:IMM)

To view the presentation, download the attached PDF.

INOVIQ - Successful completion of Share Purchase Plan (ASX:IIQ)

Highlights: -- IIQ successfully completed its share purchase plan with applications totalling A$7.293 million, exceeding its initial target of A$2 million. -- Directors exercised discretion...read more

Immutep Announces Details for Oral Presentation at ESMO Virtual Plenary Session and Webcast to Discuss Clinical Results (ASX:IMM)

SYDNEY, AUSTRALIA – July 3rd, 2024 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing nove...read more

Viewing: 16 - 30 of 200 Previous | Next